陶攀，博士，教授，博士生导师，国家海外优秀青年基金获得者、入选湖北省“百人计划”和“楚天学者”。农业微生物资源发掘与利用全国重点实验室、湖北洪山实验室固定研究人员。长期从事重大人畜共患传染病的防治、噬菌体资源开发与利用等相关研究。相关研究成果发表在Sci Adv、Nat Commun、PNAS、Adv Drug Deliv Rev、PLoS Pathog、mBio、JVI等国际学术期刊，并被Science等杂志报道。授权8项（其中国际专利1项）。承担了国家自然科学基金面上项目、海外优青、国家重点研发子课题等多项国家级科研项目。

个人学术主页

1. Google scholar：https://scholar.google.com/citations?user=BZ2BttcAAAAJ&hl=en

2. Orcid：https://orcid.org/0000-0002-0082-2229

代表性论文

1.  Li M, Sun E, Wang S, Huang Y, Song H, Kuang S, Li G, Liu Y, Xia Z, Zhang X, Han J, Dong Z, Rao V, Sun L, and Tao P*. Periplasmic gatekeeping of phage DNA entry by an rSAM enzyme matured effector with HxS repeats. Nat Commun. 2026, Mar 13. doi: 10.1038/s41467-026-70567-0.

2.  Wang S, Kuang S, Song H, Sun E, Li M, Liu Y, Xia Z, Zhang X, Wang X, Han J, V. B. Rao, Zou T, Tan C, and Tao P*. The Role of TIR Domain-containing Proteins in Bacterial Defense Against Phages. Nat Commun. 2024, 15, 7384.

3.  Wang Y, Wang C, Guan Z, Cao J, Xu J, Wang S, Cui Y, Wang Q, Chen Y, Yin Y, Zhang D, Liu H, Sun M, Jin S, Tao P*, Zou T*. DNA methylation activates retron Ec86 filaments for antiphage defense. Cell Reports. 2024, 43, 114857

4.  Tao P, Wu X, Rao V*. Unexpected evolutionary benefit to phages imparted by bacterial CRISPR-Cas9. Science Advances. 2018; 4(2): eaar4134.  

5.   Tao P, Mahalingam M, Marasa BS, Zhang Z, Chopra AK*, Rao VB*. In vitro and in vivo delivery of genes and proteins using the bacteriophage T4 DNA packaging machine. PNAS. 2013, 110(15):5846-5851.

6.   Guo P, Guo A, Dong Z, Chen C, Song H, Li M*, Tao P*. NPmut- and M2e-decorated T4 phage nanoparticles induce mucosal immunity and cross-group protection against influenza A virus. Int. J. Biol. Macromol. 2026, 151460

7.  Chen C, Li M, Guo A, Guo P, Zhang W, Gu C, Wen G, Zhou H*, and Tao P*. Addressing unexpected bacterial RNA safety concerns of E. coli produced influenza NP through CpG loaded mutant. npj Vaccines. 2025, 10 (1), 32

8. Yuan X, Dong J, Xiang Z, Zhang Q, Tao P*, and Guo A*. A Genome-Wide Screening of Novel Immunogenic TrLSDV103 Protein of Lumpy Skin Disease Virus and Its Application for DIVA. The FASEB. 2025, 39 (11), e70676  

9. Chen C, Zhang N, Li M, Guo A, Zheng Y, Humak F, Qian P*, Tao P*. Recombinant bacteriophage T4 displaying key epitopes of the foot-and-mouth disease virus as a novel nanoparticle vaccine. Int. J. Biol. Macromol. 2024, 128837

10.  Wang S, Sun E, Liu Y, Yin B, Zhang X, Li M, Huang Q, Tan C, Qian P, Rao V, Tao P*. Landscape of new nuclease-containing antiphage systems in E. coli and the counter-defense roles of bacteriophage T4 genome modifications. J. Virol. 2023, doi: 10.1128/jvi.00599-23

11. Liu Y, Dai L, Dong J, Chen C, Zhu J, Rao VB*, Tao P*. Covalent modifications of bacteriophage genome confer a degree of resistance to bacterial CRISPR systems. J. Virol. 2020, 9; 94(23): e01630-20.

12. Tao P*, Zhu J, Mahalingam M, Batra H, Rao VB*. Bacteriophage T4 nanoparticles for vaccine delivery against infectious diseases. Adv Drug Deliv Rev. 2019; 145:57-72.

其他论文

1.      M Li, P Guo, H Song, C Chen, H Zhou, P Tao*. Development of universal influenza vaccines: strategies for broadly cross-reactive influenza vaccine responses. Animal Diseases. 2025, 5 (1), 1-21

2.      GQ Zhao, YM Zhang, Y Li, SD Zhang, SJ Jiao, XY Zeng, JJ Ma, YQ Cheng, HA Wang, YX Yan, JH Sun, P Tao*, ZF Wang*. Design of Multi-Epitope Chimeric Phage Nanocarrier Vaccines for Porcine Deltacoronavirus. Veterinary Microbiology. 2025, 110487.

3.  Dong J, Zhang Q, Yang J, Zhao Y, Miao Z, Pei S, Qin H, Jing C, Wen G, Zhang A, Tao P*. BacScan: A Novel Genome-wide Strategy for Uncovering Broadly Immunogenic Proteins in Bacteria. Front Immunol. 2024, 15, 1392456.

4.    Zhu J, Tao P, Chopra AK, Rao VB*. Bacteriophage T4 as a Protein-Based, Adjuvant-and Needle-Free, Mucosal Pandemic Vaccine Design Platform. Annu Rev Virol. 2024, 11:395-420

5.   Yang J, Zhang X, Dong J, Zhang Q, Sun, Chen C, Miao Z, Zheng Y, Zhang N, Tao P*. De novo identification of bacterial antigens of a clinical isolate by combining use of proteosurfaceomics, secretomics, and BacScan technologies. Front Immunol. 2023, 14:1274027.

6.    Li M, Chen C, Wang X, Guo P, Feng H, Zhang X, Zhang W, Gu C, Zhu J, Wen G, Feng Y, Xiao L, Peng G, Rao V, Tao P*. T4 bacteriophage nanoparticles engineered through CRISPR provide a versatile platform for rapid development of flu mucosal vaccines. Antiviral Research. 2023, 217:105688.

7.     Zhu J, Batra H, Mahalingam M, Ananthaswamy N, Tao P, Wu X, Guo W, Fokine A, Rao V*. Design of bacteriophage T4-based artificial viral vectors for human genome remodeling. Nat Commun. 2023, 14:2928.

8.     Wang Y, Guan Z, Wang C, Nie Y, Chen Y, Qian Z, Cui Y, Xu H, Wang Q, Zhao F, Zhang D, Tao P, Sun M, Yin P, Jin S, Wu Shan*, Zou T*. Cryo-EM structures of Escherichia coli Ec86 retron complexes reveal architecture and defence mechanism. Nat Microbiol. 2022. 7(9):1480-1489

9.     Li M, Guo P, Chen C, Feng H, Zhang W, Gu C, We G, Rao VB, Tao P*. Bacteriophage T4 Vaccine Platform for Next-generation Influenza Vaccine Development. Front Immunol. 2021. 12:745625. doi: 10.3389/fimmu.2021.745625

10.   Dong J, Chen C, Liu Y, Zhu J, Li M, Rao VB*, Tao P*. Engineering T4 bacteriophage for in vivo display by type V CRISPR-Cas genome editing. ACS Synth Biol. 2021. 10(10):2639-2648. doi: 10.1021/acssynbio.1c00251

11.   Wu X, Zhu J, Tao P, Rao VB*. Bacteriophage T4 Escapes CRISPR Attack by Minihomology Recombination and Repair. mBio. 2021. 12 (3), e01361-21

12.   Fang Q, Tang WC, Tao P, Mahalingam M, Fokine A, Rossmann MG, Rao VB*. Structural morphing in a symmetry-mismatched viral vertex. Nat Commun. 2020,11(1):1713.

13.   Chen Y, Yang L, Yang D, Song J, Wang Can, Sun E, Gu C, Chen H, Tong Y*, Tao P*, Wu B*. Specific Integration of Temperate Phage Decreases the Pathogenicity of Host Bacteria. Front. Cell. Infect. Microbiol. 2020, 10:14.

14.   Tao P*, Zhu J, Mahalingam M, Batra H, Rao VB*. Bacteriophage T4 nanoparticles for vaccine delivery against infectious diseases. Adv Drug Deliv Rev. 2019; 145:57-72.

15.   Zhu J, Tao P, Mahalingam M, Sha J, Kilgore P, Chopra AK, Rao V*. A prokaryotic-eukaryotic hybrid viral vector for delivery of large cargos of genes and proteins into human cells. Sci Adv. 2019, 5(8): eaax0064.

16.   Tao P, Mahalingam M, Zhu J, Moayeri M, Sha J, Lawrence WS, Leppla SH, Chopra AK, Rao VB*. A Bacteriophage T4 Nanoparticle-Based Dual Vaccine against Anthrax and Plague. mBio. 2018; 9(5). pii: e01926-18. 

17.   Tao P*, Wu X, Tang W, Zhu J, Rao VB*. Engineering of Bacteriophage T4 Genome Using CRISPR-Cas9. ACS Synth Biol. 2017. doi: 10.1021/acssynbio.7b00179.

18.    Tao P, Mahalingam M, Zhu J, Moayeri M, Kirtley ML, Fitts EC, Andersson JA, Lawrence WS, Leppla SH, Chopra AK, Rao VB. A Bivalent Anthrax–Plague Vaccine That Can Protect against Two Tier-1 Bioterror Pathogens, Bacillus anthracis and Yersinia pestis. Front Immunol. 2017 8:687.

19.   Dai L, Li Z, Tao P*. Evolutionary Analysis of Tembusu Virus: Evidence for the Emergence of a Dominant Genotype. Infect Genet Evol. 2015, 32: 124-19.

20.   Tao P, Mahalingam M, Kirtley ML, van Lier CJ, Sha J, Yeager LA, Chopra AK*, Rao VB*. Mutated and bacteriophage T4 nanoparticle arrayed F1-V immunogens from Yersinia pestis as next generation plague vaccines. PLoS Pathog. 2013, 9(7): e1003495.